Discovered new, cleavable, kagome metal with complex antiferromagnetism, competing for stability against a related family of “shurikagome” metals. Provides new material platform for the interplay of ...

多年来，浙江大学杨兵研究员实验室一直聚焦于使用共价捕获的方式，来研究弱的、瞬时蛋白质的相互作用。图 | 杨兵（来源：杨兵）之前，杨兵在从事博士后研究的时候，曾在美国加州大学旧金山分校王磊教授实验室开发了可富集的化学交联非天然氨基酸 ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Specific design of protease inhibitors based on the transition-state peptidomimetic principle — replacement of the peptide linkage by a non-cleavable bond — and aided by structures of the ...

While its target is the same as that of Enhertu, its payload is a tubulin binder known as amberstatin 269 rather than the topoisomerase 1 inhibitor deruxtecan, and its linker is non-cleavable ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...